Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 37,514 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase 2 Clear all
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

NCT01751048
View directory record Official record
Conditions
Leishmaniasis
Interventions
GLA-SE, LEISH-F3, MPL-SE, SE
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 30, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

NCT06238648
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Rochester, Minnesota • St Louis, Missouri • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 30, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

NCT01357655
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, BMS-833923
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 30, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT00714948
View directory record Official record
Conditions
Bladder Cancer, URINARY BLADDER
Interventions
gemcitabine and cisplatin plus sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Oct 30, 2026, 6:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

NCT07390955
View directory record Official record
Conditions
HIV
Interventions
ePGT121v1-LS (IV), PGDM1400LS (IV), VRC07-523LS (IV), ePGT121v1-LS (SC), PGDM1400LS (SC), VRC07-523LS (SC)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Recruiting Phase 1 Interventional

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

NCT03922555
View directory record Official record
Conditions
Neurological Cancer
Interventions
ASTX727
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

NCT00016315
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
19
States / cities
Oakland, California • Miami, Florida • Dubuque, Iowa + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 30, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT05139615
View directory record Official record
Conditions
Acute Heart Failure With Reduced Ejection Fraction
Interventions
APD418, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 30, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

NCT06802315
View directory record Official record
Conditions
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
Interventions
Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)
Radiation · Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Active, not recruiting Phase 3 Interventional

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

NCT03811015
View directory record Official record
Conditions
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Nivolumab, Patient Observation, Positron Emission Tomography
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
727
States / cities
Fairhope, Alabama • Mobile, Alabama • Anchorage, Alaska + 462 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT03603808
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Not listed Phase 1 Interventional

NMES and Chronic Ankle Instability

NCT04322409
View directory record Official record
Conditions
Chronic Ankle Instability
Interventions
Neuromuscular Electrical Stimulation, Transcutaneous Electrical Nerve Stimulation
Device
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

NCT00469209
View directory record Official record
Conditions
Myeloma
Interventions
Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan, Vitamin C (Ascorbic Acid)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional

Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00293332
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, docetaxel, conventional surgery
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

NCT02503332
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan, Sham Procedure
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 30, 2026, 6:53 AM EDT
Withdrawn Phase 2 Interventional

Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

NCT00006263
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, temozolomide
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 30, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

A Vaccine Trial for Low Grade Gliomas

NCT02358187
View directory record Official record
Conditions
Low Grade Glioma
Interventions
Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Biological
Lead sponsor
James Felker
Other
Eligibility
12 Months to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Active, not recruiting Phase 2 Interventional

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

NCT05384587
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Study of Urate Elevation in Parkinson's Disease, Phase 3

NCT02642393
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

NCT00002514
View directory record Official record
Conditions
Leukemia
Interventions
sargramostim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, imatinib mesylate, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
15 Years to 65 Years
Enrollment
1,929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
94
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Peer Navigator for Early Psychosis for Black Families

NCT05284721
View directory record Official record
Conditions
Family Members
Interventions
Family Peer Navigator for Early Psychosis, Care Coordination
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

NCT00095121
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 30, 2026, 6:53 AM EDT